IOL implantation improves sleep quality

Article

Removal of a cataract and implantation of an intraocular lens (IOL) improves overall sleep quality and sleep latency, according to a study published online before print.

Removal of a cataract and implantation of an intraocular lens (IOL) improves overall sleep quality and sleep latency, according to a study published online before print in Investigative Ophthalmology and Visual Science.

Researchers in the UK were seeking information on how the melanopsin-based photosensitive retinal ganglion cells (pRGC's) regulate sleep/wake timing in patients who have cataracts. They used the Pittsburgh Sleep Quality Index (PSQI) to assess quality of sleep in 961 patients undergoing cataract surgery. The patients received either an ultraviolet blocking (UVB) clear IOL (498 patients) or a blue-filtering (BF) IOL (463 patients). The patients completed the PSQI questionnaires 1 month preoperatively and 1, 6 (UVB-IOL patients only) and 12 months postoperatively.

The researchers found that cataract removal - regardless of the type of IOL implanted - improved overall sleep quality significantly 1 month postoperatively. Sleep latency (the shortening in time to fall asleep) also improved, and the improvement was sustained at 6 and 12 months postoperatively.

"The key finding of this study is the sustained improvement in sleep latency after surgery irrespective of IOL type implanted. This result highlights a significant benefit of cataract surgery in addition to improvement in visual acuity," the researchers wrote.

To read the full study, visit the journal's website.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.